SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as analysts adjust price targets and ratings, following news of Piper Sandler and Stephens & Co. setting overweight ratings. The community highlights potential for new store openings and expansion into electric vehicle services, viewing it as a safe, long-term investment. Bullish sentiment suggests potential to test all-time highs, with some eyeing it as an 'easy money' opportunity.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community discusses its potential, particularly following integrations with Abstract Chain and Shogun, which enable new functionalities like cross-chain triggers and AI-driven DeFi automation.  Enthusiasm centers around the project's technology and speculation about future listings, along with anticipation for the sunsetting of $PRQ, which some believe is currently limiting REACT's price action. Some community members express very high hopes for the token.

ProShares Trust - ProShares VIX Mid-Term Futures ETF

ProShares VIX Mid-Term Futures ETF

VIXM is trending as traders discuss potential government shutdowns and the accumulation of volatility insurance amid frothy market conditions. Community members are exploring VIXM leaps and comparing it to other volatility hedges like $VIXY, noting its potential for minimal decay and suitability for longer holding periods. Some traders suggest VIXM could be a strategic play given historical patterns of increased volatility in October.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as it approaches its halving event, with the community actively discussing its potential for significant gains and its privacy features in light of increased regulatory scrutiny on crypto. Some are drawing comparisons to Bitcoin's early days, while others point to ZEC's shielded transactions as a key differentiator for institutional adoption. There's also excitement around new integrations and developments within the Zcash ecosystem.

Great Elm Capital Corp

Great Elm Capital is trending due to discussions around its high dividend yield and recent news of insider buying. The stock's sensitivity to interest rates and its classification as a business development company are also being considered by the community. Some are discussing its potential as a value investment, while others are weighing the impact of a recent public offering and overbought RSI signals.

Hasbro, Inc. engages in the provision of children and family leisure time products and services with a portfolio of brands and entertainment properties. The firm's brands of toys include Power Rangers, Magic: The Gathering, Monopoly, My Little Pony, Nerf, Play-Doh and Transformers. It operates through the following segments: Consumer Products, Wizards of the Coast and Digital Gaming, Entertainment, and Corporate and Other. The Consumer Products segment markets and sells toys and game products around the world. It also promotes brands through the out-licensing of trademarks, characters and other brand and intellectual property rights to third parties, and through the sale of branded consumer products such as toys and apparel. The Wizards of the Coast and Digital Gaming segment promotes the company's brands through the development of trading cards, role-playing and digital game experiences based on Hasbro and Wizards of the Coast properties. The Entertainment segment develops and distributes entertainment content including film, scripted and unscripted television, children's programming, digital content, and live entertainment. The Corporate and Other segment includes the management and administrative services to its principal reporting segments. The company was founded by Henry Hassenfeld and Hilal Hassenfeld in 1923 and is headquartered in Pawtucket, RI.

Hasbro, Inc.

Hasbro ($HAS) is trending due to unusual options activity signaling bullish sentiment and upcoming earnings, particularly driven by the performance of Magic: The Gathering. Community members are discussing the potential impact of the Lord of the Rings set and digital gaming growth on Hasbro's financials. As a consumer discretionary stock, Hasbro is also being considered in light of potential Fed rate cuts.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention as it expands across multiple chains like Solana, BNB, and Base. Community members highlight its fully circulated supply and deflationary burn mechanism, contributing to its increasing popularity. Traders are watching its growing presence on various exchanges, with some suggesting it could be the next big meme coin.

Roundhill ETF Trust - Roundhill TSLA WeeklyPay ETF

Tradr 1.5X Long TSLA Weekly ETF

TSLW is trending as traders discuss its weekly dividend payouts and technical analysis, with some expressing interest in accumulating shares during dips. Community members are actively sharing their strategies, including adding to positions and monitoring trend lines for potential buying opportunities, while also comparing TSLW's performance against similar leveraged ETFs.

United States Commodity Funds LLC - United States Gasoline Fund LP

$UGA is trending due to discussions around gasoline prices, potential breakouts, and actionable alerts for call options, particularly those expiring in June 2026. Community members are also weighing in on factors influencing gas prices, including China's demand, OPEC production, and geopolitical events. Bullish sentiment is noted amid strong trading volumes, while analysts discuss the potential for rising gasoline prices.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending as traders discuss its potential as an Aero competitor and highlight its recent price action. The community is focused on its launch on Base as a DUNA protocol with locked tokenomics and revenue flow, as well as speculation around potential exchange listings and social media buzz driving gains. Some are drawn to its low market cap and potential for quick gains relative to other crypto projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Sangamo (SGMO) a New Buy Stock

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

Stock Index Futures Slip as Tariff-Driven Selloff Continues, U.S. Jobs Report and Powell Speech in Focus

June S&P 500 E-Mini futures (ESM25) are down -0.84%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.52% this morning, pointing to a continued selloff on Wall Street following U.S. President Donald Trump’s announcement of sweeping tariffs, while investors await the key U.S. payrolls report and remarks from Federal Reserve Chair Jerome Powell.

Shares of Eli Lilly &amp; Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by fears of a global economic fallout from President Donald Trump’s reciprocal tariff blitz.However, retail investors took heart in the fact that the pharmaceutical industry suffered a relatively lighter blow compared to sectors like technology and manufacturing, as it was largely spared from the government’s targeted tariff list.On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’<figure class="image"><img style="aspect-ratio:1314/320;" src="https://news.stocktwits-cdn.com/LLY_sentiment_and_message_volume_on_April_3_png_0331ef626f.webp" alt="LLY sentiment and message volume on April 3.png" width="1314" height="320"><figcaption>LLY sentiment and message volume on April 3. | source: Stocktwits</figcaption></figure>“LLY isn’t even affected. Loading up on calls at the open!” one user posted early Thursday when the stock was still in the green.<stembedurl>https://stocktwits.com/DayTrader6969/message/610222644</stembedurl>Another user pointed out that Trump had specifically highlighted Lilly as a company investing in U.S. infrastructure and job creation, suggesting it could ultimately benefit from the administration’s policies.<stembedurl>https://stocktwits.com/MrChoudhury/message/610228354</stembedurl>Back in February, when Trump threatened to impose tariffs on drug imports, Lilly unveiled a plan to invest $27 billion on new plants in the United States over the next five years.However, as drugmakers dig through the fine print of Trump's sweeping executive order — which imposes a 10% baseline duty on most imports — uncertainty remains over whether the pharmaceutical industry will be completely spared.Media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/pharma-stocks-up-on-us-tariff-exemptions-but-analyst-flags-a-46b-import-cost-risk-3964936">reports</a> suggest a U.S. official hinted that a separate round of tariffs targeting pharmaceuticals is still on the table.According to Bernstein analysts, if country-specific tariffs are applied, the pharmaceutical industry could face up to $46 billion in additional import costs.For now, investors seem to be taking a small win in stride.Retail traders on Thursday also zeroed in on Lilly’s newly inked licensing deal with Sangamo Therapeutics for its adeno-associated virus capsid,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sgmo-stock-falls-after-q4-2024-earnings-miss/ch7KGZ9Rbca">STAC-BBB</a>, designed to improve the delivery of IV-administered genomic medicines for neurological diseases.The deal grants Lilly exclusive global rights to use STAC-BBB for one initial central nervous system target, with the option to expand to four more for additional fees.Lilly's stock has gained a little over 1% this year, while the Dow Jones U.S. Health Care Index is up over 2.5% and the S&amp;P 500 Health Care Index has risen over 4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption

On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 

Equity

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following disappointing quarterly earnings, but retail investors held their bullish ground.Sangamo reported a fourth-quarter adjusted loss per share of $0.11, narrowing significantly from a loss of $0.34 a year earlier. However, this was worse than Wall Street's expected $0.09 per share loss.Revenue of $7.6 million also fell short of the consensus estimate of $11.7 million.&nbsp;CEO Sandy Macrae emphasized the company's progress over the past year, notably securing FDA approval for clinical trials of ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN)."We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future," he said.Macrae added that 2025 will be a pivotal year, with plans to begin patient enrollment and dosing for the iSFN clinical study by midyear.&nbsp;The company also aims to submit a Biologics License Application (BLA) for its Fabry disease program in the second half of the year.On Stocktwits, sentiment for Sangamo ended Monday on an 'extremely bullish' note, with message volume exploding by 1200% from a day earlier.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMO_sentiment_and_message_volume_as_of_March_17_png_2c103aadf6.webp" alt="SGMO sentiment and message volume as of March 17.png" width="1316" height="302"><figcaption>SGMO sentiment and message volume as of March 17. | source: Stocktwits</figcaption></figure>Several optimistic users expressed confidence in Macrae's remarks about securing a third potential agreement with a major pharmaceutical company for its adeno-associated virus (AAV) capsid, STAC-BBB. The technology is designed to enhance the delivery of intravenously administered genomic medicines for specific neurological conditions.Sangamo has already licensed STAC-BBB to Roche's Genentech and Astellas Pharma.<stembedurl>https://stocktwits.com/BurkeTheBizarre15/message/608344985</stembedurl><stembedurl>https://stocktwits.com/Who_is_JohnnyGalt/message/608344869</stembedurl>Sangamo has been under pressure since December, when Pfizer ended a hemophilia drug development partnership, citing slow patient uptake for such therapies.Shares of the company have shed only about 1% this year but are up 20% over the past 12 months.According to Koyfin, five out of eight analysts covering the stock rate it 'buy' or 'strong buy', while the rest recommend 'hold'.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.6829
Prev Close	$0.70
Open	$0.71
Dividend Yield	0.00%
50-Day Moving Average	$0.557
Beta	1.59
Avg. Volume	5.53M
PE Ratio	-2.40

52-Week High	$3.18
52-Week Low	$0.4111
Market Capitalization	$206.04M
EPS (Annual)	-$0.4856
Price to Book	9.50
Revenue Per Employee	$315,846.99
Enterprise Value/EBITDA	N/A

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMO Sangamo Therapeutics Inc